 | | Vol. 13.36 – 13 September, 2022 |
| |
|
|
| Investigators developed experimentally tractable human and murine disease models, investigated the transcriptional consequences of EVI1 withdrawal in vitro and in vivo, and performed the first genome-wide CRISPR screens in EVI1-dependent AML.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that genetic deletion of IL-1 receptor 1 normalized peripheral blood counts, reduced splenomegaly, and ameliorated bone marrow fibrosis in homozygous Jak2V617F mouse model of myelofibrosis.
[Nature Communications] |
|
|
|
| Scientists identified tetraspanin CD37, a prognostic marker for aggressive B cell lymphoma, as essential membrane-localized inhibitor of fatty acid metabolism.
[Nature Communications] |
|
|
|
| Using lipopolysaccharide (LPS)-induced emergency granulopoiesis as a model, the authors showed that failed expansion was intrinsic to FZD6-deficient hematopoietic stem/progenitor cells but also required a FZD6-deficient environment.
[Cell Reports] |
|
|
|
| NY-ESO-1-specific T cell receptor (TCR)-T cells could efficiently eliminate AML cell lines and primary AML blasts in vitro by targeting the decitabine-induced NY-ESO-1 expression.
[Oncogene] |
|
|
|
| Researchers used acid ceramidase (Ac)-deficient mice with ubiquitously increased ceramide levels to elucidate the role of endogenous Ac activity in a murine malaria model. Ablation of Ac les to alleviated parasitemia associated with decreased T cell responses in the early phase of Plasmodium yoelii infection.
[eLife] |
|
|
|
| The authors analyzed the roles of CXCR4, CD74, and migration-inhibitory factor (MIF) in chronic lymphocytic leukemia (CLL). Mononuclear cells from patients with hematological malignancies were analyzed for co-expression of CXCR4 and CD74 by flow cytometry.
[Experimental Hematology] |
| |
|
|
| Scientists evaluated 92 patients with mast cell leukemia (MCL) from the European Competence Network on Mastocytosis registry. 31 patients had a diagnosis of MCL with an associated hematologic neoplasm
[Blood Advances] |
|
|
|
|
| Investigators review the role of ASXL1 and ASXL2 in normal and malignant hematopoiesis by summarizing the findings of mouse model systems and discussing their underlying molecular mechanisms.
[Journal of Hematology & Oncology] |
|
|
|
|
| BioLineRx Ltd. announced that they have submitted its to the FDA for Motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients.
[BioLineRx Ltd.] |
|
|
|
|
| October 20 – 21, 2022
Turin, Italy |
|
|
|
|
|
| | The Jackson Laboratory – Bar Harbor, Maine, United States |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | University of Wisconsin-Madison – Madison, Wisconsin, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | The University of Chicago – Chicago, Illinois, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
